HealthCare Global Enterprises Limited has confirmed the successful allotment of Equity Shares following its recent Rights Issue, which concluded on March 25, 2026. The Rights Issue Committee, meeting on March 27, 2026, approved the allotment of 82,94,566 Equity Shares. The issue price was set at ₹512 per share, comprising a face value of ₹10 and a premium of ₹502. This action increased the company’s paid-up capital from ₹141.00 crore to ₹149.30 crore.
Outcome of the Rights Issue Committee Meeting
HealthCare Global Enterprises Limited has announced the conclusion of its Rights Issue process. Following the closure of the issue on March 25, 2026, the Rights Issue Committee convened on March 27, 2026, to finalize the basis of allotment.
The Committee formally approved the allotment of 82,94,566 fully paid-up Equity Shares to eligible shareholders and/or renouncees. The allotment was executed based on the terms detailed in the Letter of Offer.
Key Financial Terms of the Allotment
The Equity Shares were issued at a price of ₹512 per share. This total price includes the nominal Face Value of ₹10 and a substantial premium of ₹502 per Equity Share.
Impact on Paid-Up Share Capital
The successful allotment resulted in a direct increase in the company’s paid-up equity share capital. The capital rose from the pre-issue amount of ₹1,41,00,76,370 (comprising 14,10,07,637 shares) to the post-issue amount of ₹1,49,30,22,030 (comprising 14,93,02,203 shares).
The details comparing the capital structure before and after the rights issue are summarized below:
Pre and Post-Issue Share Capital Details
The following table illustrates the change in the structure:
- Paid-up share capital (Pre-Rights Issue): 14,10,07,637 Equity Shares, Face Value of ₹10.
- Paid-up share capital (Post-Rights Issue): 14,93,02,203 Equity Shares, Face Value of ₹10.
Corporate Filing Summary
The committee meeting for this final approval commenced at 8:10 p.m. and concluded at 10:00 p.m. on the date of the announcement.
Details of Securities Issued
The issuance constituted a Rights Issue specifically targeting eligible equity shareholders as of the Record Date, which was set as March 02, 2026. No cancellation or termination of this issuance proposal was reported.
Source: BSE
